Allergan gel-based stents are treating glaucoma

An Allergan-developed gelatin-based stent is showing potential to treat glaucoma in a quicker and safer environment, according to new research from the University of Michigan. Glaucoma is a disease that damages the eye’s optic nerve and can cause vision loss and blindness. Medicines in the form of eyedrops or pills can be used to treat

The top medtech stories of early 2017

The new Trump administration and Republican Congress – and all the accompanying change and uncertainty –is the major story for the medical device industry. But there are many other medtech stories worth noting from the first quarter of 2017. There was an FDA warning over Abbott’s Absorb bioresorbable stent, a continued spate of M&A deals, a

Pages: 1 2 3 4 5 6

Why Allergan CEO Brent Saunders values friendliness

In between business meetings this week, Brent Saunders stopped by the Medical Device Investor Forum hosted by OCTANe in Irvine, Calif., to chat with Jim Mazzo. The two, who have known each other for years, had a discussion about the business of acquisitions, R&D, tax inversion, and other subjects. Of course, in the background, Allergan is